In 2021, research led by Ryan Flynn, MD, Ph.D., and his mentor, Nobel laureate Carolyn Bertozzi, Ph.D., opened a new chapter ...

Researchers show that glycoRNAs, uncovered by the lab of Nobel Laureate, Carolyn Bertozzi, can be used to fight cancer.

Scientists have discovered a potential new way to treat one of the most aggressive blood cancers, offering hope to thousands of patients.A study from the University of Cambridge, published in the ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

It comes a few days after the company's shares came under pressure from the results of a phase 1/2 trial of Revuforj in relapsed or refractory mutant NPM1 acute myeloid leukaemia (AML), a follow ...

Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.

“This NDA submission brings us one step closer to our goal of advancing ziftomenib to market as a new therapeutic option for adult patients with R/R NPM1-m AML, a devastating disease for which ...

The submission, made on March 31, 2025, targets adult patients with relapsed or refractory AML harboring a nucleophosmin 1 (NPM1) mutation. Ziftomenib, a once-daily oral menin inhibitor ...

With collaborators at the Cambridge (UK) Stem Cell Institute, led by Konstantinos Tzelepis, PhD, and Maria Eleftheriou, PhD, they show that one RNA-binding protein on the cell surface, NPM1 ...

Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq ...